{"entity":{"id":"ultima-genomics","kind":"company","name":"Ultima Genomics","aka":[],"tldr":"Open-wafer sequencing (UG 100) claiming a $100 genome, aimed at population-scale and deep ctDNA sequencing.","summary":"Ultima Genomics, based in Fremont, California, makes the UG 100 open-wafer sequencer, marketed on the claim of a 100 dollar genome and aimed at population-scale and deep circulating tumour DNA sequencing. It launched commercially in 2024, is used by Exact Sciences and others for high-depth cell-free DNA, and raised more than 600 million dollars in 2022 with further rounds since. OnCo links it to new short-read sequencing platforms. Whether cheaper sequencing at depth makes blood-based cancer detection and residual disease testing affordable at population scale is the open question. The short-read platforms page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.ultimagenomics.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["next-gen-short-read-platforms"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Fremont, CA","country":"US","companyType":"diagnostics","website":"https://www.ultimagenomics.com","investors":[],"funding":[]},"route":"/companies/ultima-genomics/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"next-gen-short-read-platforms","kind":"technology","name":"New short-read sequencing platforms","route":"/technologies/next-gen-short-read-platforms/"}]}}